slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 17,911-17,940
Pages 3,950
Rows per page 30
Component
17,911-17,940 of 118,471
238
The slide uses direct quotes from an ex-employee to undermine the credibility of the company's clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
249
The slide uses direct quotes from a KOL to undermine the credibility of the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
275
The slide uses direct quotes from a researcher to undermine the perceived positive sentiment of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
279
The slide uses highlighted quotes from a former senior medical affairs employee to undermine the commercial viability of Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
288
The slide uses direct quotes from a KOL to build a case against the safety profile of the drug Vykat, specifically highlighting the risk of electrolyte depletion when combined with diuretics.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
297
The slide uses Q&A transcripts to undermine the competitive advantage of the Vykat tablet formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
298
The slide uses a Q&A format to highlight the investigator's lack of enthusiasm and low patient uptake.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
299
The slide uses direct Q&A transcripts to highlight the investigator's negative sentiment and concerns about patient safety (diabetes/hyperglycemia).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
302
The slide uses a Q&A format to highlight potential misconduct by the company.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
308
The slide uses direct quotes from a trial investigator to undermine the validity of clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
314
The slide uses a Q&A format to highlight expert opinion against the subject drug (DCCR/Vykat).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
329
The slide uses a Q&A format to document expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
336
The slide uses a Q&A format to highlight the investigator's reluctance and admission of clinical risks.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
345
The slide uses expert quotes to undermine the company's claims regarding the drug's safety profile and market potential.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
349
The slide uses direct quotes to undermine the market potential and safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
352
The slide uses direct quotes to highlight the expert's negative sentiment toward the drug and the clinical trial methodology.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
359
The slide uses direct quotes to undermine the credibility of the company's sales representatives and the drug's market reception.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
366
The slide uses direct quotes to highlight a potential discrepancy between marketing claims and clinical reality.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
372
The slide uses a Q&A transcript format to highlight potential misinformation or manipulation by study investigators regarding drug efficacy timelines.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
387
The slide uses Q&A transcripts to undermine the credibility of the company's marketing claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
393
The slide uses highlighted text to emphasize key concerns about Vykat's safety profile and Miller's private skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
395
The slide uses a Q&A format to highlight the physician's reluctance to prescribe Vykat and their familiarity with the risks of diazoxide.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
406
The slide uses a Q&A format to highlight physician reluctance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 3 hits
12
The slide uses a 'Spy The Lie' framework to interpret CEO responses as deceptive.TransMedics (TMDX) · Scorpion Capital
Research note Short seller Beat · Critique of TransMedics Group Inc.3 hits
25
The slide uses a 'villain critique' approach to frame the company's business model as a 'government pay scam'.TransMedics (TMDX) · Scorpion Capital
Research note Short seller Beat · Exposure of Contradictions3 hits
51
The slide uses a 'Q&A' format to document expert interviews, highlighting the lack of choice for customers.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
61
The slide uses direct quotes from KOLs to build a case against the company's pricing model.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
75
The slide uses Q&A transcripts to expose a contradiction between operational efficiency and the company's new logistics model.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
77
The slide uses a Q&A format to highlight specific allegations of corporate misconduct.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
90
The slide uses a testimonial to highlight a shift from a collaborative 'backyard relationship' to a profit-driven 'utilization at all costs' model.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits